The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform
T Masuhr - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal Extract WS 1473 and Urtica Extract WS 1031 in urologic specialty practices
Fortschritte der Medizin, 1995Co-Authors: H J Schneider, E Honold, T MasuhrAbstract:In an open, prospective, multicentric observational study involving 419 specialist urological practices, the efficacy and tolerability of a combination preparation comprising Sabal Extract WS 1473 and Urtica Extract WS 1031 were investigated in 2080 patients with Alken's stage I or II benign prostatic hyperplasia. A before-and-after comparison revealed an improvement in the pathological findings and in the obstructive and irritative symptoms. For the most part, the efficacy and tolerability of the preparation were assessed by the physician to be "very good" or "good". At the end of treatment, most patients indicated an improvement in their prostatic symptomatology and in general quality of life. Fifteen patients (0.72%) were suspected of having developed mild side effects.
H J Schneider - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal Extract WS 1473 and Urtica Extract WS 1031 in urologic specialty practices
Fortschritte der Medizin, 1995Co-Authors: H J Schneider, E Honold, T MasuhrAbstract:In an open, prospective, multicentric observational study involving 419 specialist urological practices, the efficacy and tolerability of a combination preparation comprising Sabal Extract WS 1473 and Urtica Extract WS 1031 were investigated in 2080 patients with Alken's stage I or II benign prostatic hyperplasia. A before-and-after comparison revealed an improvement in the pathological findings and in the obstructive and irritative symptoms. For the most part, the efficacy and tolerability of the preparation were assessed by the physician to be "very good" or "good". At the end of treatment, most patients indicated an improvement in their prostatic symptomatology and in general quality of life. Fifteen patients (0.72%) were suspected of having developed mild side effects.
E Honold - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal Extract WS 1473 and Urtica Extract WS 1031 in urologic specialty practices
Fortschritte der Medizin, 1995Co-Authors: H J Schneider, E Honold, T MasuhrAbstract:In an open, prospective, multicentric observational study involving 419 specialist urological practices, the efficacy and tolerability of a combination preparation comprising Sabal Extract WS 1473 and Urtica Extract WS 1031 were investigated in 2080 patients with Alken's stage I or II benign prostatic hyperplasia. A before-and-after comparison revealed an improvement in the pathological findings and in the obstructive and irritative symptoms. For the most part, the efficacy and tolerability of the preparation were assessed by the physician to be "very good" or "good". At the end of treatment, most patients indicated an improvement in their prostatic symptomatology and in general quality of life. Fifteen patients (0.72%) were suspected of having developed mild side effects.
L. Ebeling - One of the best experts on this subject based on the ideXlab platform.
-
Long-term drug treatment of benign prostatic hyperplasia - results of a prospective 3-year multicenter study using Sabal Extract IDS 89.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 1996Co-Authors: D. Bach, L. EbelingAbstract:A 3-year prospective multicenter study on Sabal Extract IDS 89 was carried out to evaluate its potential and limitations as phytotherapy in the treatment of benign prostatic hyperplasia (BPH). The results obtained from 435 patients confirm its sustained therapeutic efficacy. A marked symptomatic improvement, that included a 50% reduction in residual urine and a 6.1 ml/sec increase in peak urinary flow rate due to therapy was observed. Both physicians and patients voted its efficacy as good or very good in over 80% of the cases, and the drug was well tolerated by 98% of the patients. The clinical status of BPH and thus the quality of life of 4 out of 5 patients was markedly improved by long-term IDS 89 therapy. Furthermore, the deterioration rate at the end of the 3-year treatment period was significantly lower than in untreated BPH subjects. It is therefore concluded that long-term IDS 89 therapy can also reduce the incidence of surgery.
D. Bach - One of the best experts on this subject based on the ideXlab platform.
-
Long-term drug treatment of benign prostatic hyperplasia - results of a prospective 3-year multicenter study using Sabal Extract IDS 89.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 1996Co-Authors: D. Bach, L. EbelingAbstract:A 3-year prospective multicenter study on Sabal Extract IDS 89 was carried out to evaluate its potential and limitations as phytotherapy in the treatment of benign prostatic hyperplasia (BPH). The results obtained from 435 patients confirm its sustained therapeutic efficacy. A marked symptomatic improvement, that included a 50% reduction in residual urine and a 6.1 ml/sec increase in peak urinary flow rate due to therapy was observed. Both physicians and patients voted its efficacy as good or very good in over 80% of the cases, and the drug was well tolerated by 98% of the patients. The clinical status of BPH and thus the quality of life of 4 out of 5 patients was markedly improved by long-term IDS 89 therapy. Furthermore, the deterioration rate at the end of the 3-year treatment period was significantly lower than in untreated BPH subjects. It is therefore concluded that long-term IDS 89 therapy can also reduce the incidence of surgery.
